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E-mail address: masayuki@med.u-ryukyu.ac.jp (MThe 2-oxoglutarate and iron dependent dioxygenase family are crucial for cellular adaptation to
changes in oxygen concentration. We found that cells with OGFOD1 gene silencing in this family
showed resistance to cell death under ischemia, and cDNA microarray analysis of OGFOD1 knockout
human cells revealed downregulation of ATPAF1. Although reintroduction of the OGFOD1 wild-type
gene to OGFOD1 KO cells restored ATPAF1 mRNA levels, the catalytically inactive OGFOD1 mutants
did not. Furthermore, introduction of ATPAF1 gene to OGFOD1 KO cells induced ischemic cell death.
Thus, OGFOD1 plays an important role in ischemic cell survival and an OGFOD1 iron binding residue
is required for ATPAF1 gene expression.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction and cardiomyocyte serve to enhance glucose uptake and metabo-Metazoans can sense the oxygen concentration and respond to
hypoxia with adaptive changes in gene expression relating to angi-
ogenesis and glycolysis. This gene expression is induced by hypoxic
inducible factor (HIF) [1,2]. Under normoxic conditions, HIF (HIF-
1a and HIF-2a) are hydroxylated by prolyl hydroxylase (PHDs) of
the 2-oxoglutarate and iron dependent dioxygenase (2-OG-Fe(II)
dioxygenase) family, and then hydroxylated HIF is degraded by a
proteasome through interaction with the pVHL E3 ubiquitin ligase
complex [3]. Another 2-OG-Fe(II) dioxygenase, factor inhibiting
HIF (FIH) hydroxylates an asparagine residue of HIF [4,5]. FIH mod-
ulates the transcriptional activation rather than stabilization of
HIF, preventing its interaction with the transcriptional co-activator
p300 that potentially reduces HIF transcriptional activity [5,6].
However, oxygen-dependent hydroxylation of HIF is reduced in
hypoxia, resulting in the stabilization, activation [3,5,7], and induc-
tion of gene expression such as glucose transporters and vascular
endothelial growth factor (VEGF). In the hypoxic and ischemic car-
diomyocyte, the expression of glucose transporters was increasedchemical Societies. Published by E
utarate and iron dependent
ibiting HIF; OGD, oxygen and
ellular Physiology, University
ara, Nishihara, Okinawa 903-
. Matsushita).lism for protection from hypoxic/ischemic injury [8,9]. VEGF also
protects motor neurons from growth factor deprivation and hydro-
gen peroxide treatment in vitro and from ischemia in vivo [10,11].
Drug studies have reported that inhibitor, dimethyloxalylglycine
(DMOG), for PHDs and FIH delay cell death caused by NGF depriva-
tion in a stroke model [12,13]. DMOG is 2-oxoglutarate analogs and
inhibit the activity of 2-oxoglutarate-dependent dioxygenases
through the competitive binding with 2-oxoglutarate to active site
[4]. Thus, it is thought that regulation of PHDs and FIH might also
be one of the survival responses under hypoxia/ischemia.
To discover the novel 2-OG-Fe(II) dioxygenases candidate in
ischemic survival, we screened this family using an siRNA library.
In this study, OGFOD1 (FLJ10826) gene-silenced cells showed sig-
niﬁcant resistance to cell death in ischemia, indicating a role of
OGFOD1 in ischemic cell survival.
2. Materials and methods
See Supplementary data.
3. Results
3.1. siRNA library screening
Ischemia is complex physiological processes, in which multiple
changes contribute to cellular adaptation. To study cell survivallsevier B.V. All rights reserved.
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oxygen and glucose deprivation (OGD) conditions to induce ische-
mia. Cell death under OGD was prevented by the 2-OG-Fe(II) diox-
ygenase inhibitor DMOG in a dose-dependent manner (Fig. 1A).
Therefore, we used the siRNA library of the 2-OG-Fe(II) dioxygen-
ase family (Table S1) to discover signiﬁcant genes responsible for
cell survival under OGD. HeLa cells were added to the well contain-
ing mixture of siRNA and transfection reagent (Fig. 1B). After 48 h
of culture, cells were exposed to OGD conditions and cell survival
was measured. We established a cut-off point (absorbance of 2.3)
in the siRNA library screening based on the value of cell viability
using 2 mM DMOG, and obtained knockdown of ALKBH, DEPC-1,
PHF8, ASPH, FLJ10826, and JMJD2B genes in HeLa cells with the
same or more viability as 2 mM DMOG-treated cells under OGD
(Fig. 1A and C). While knockdown of HIF1AN and EGLN2 (also
known as FIH and PHD1) showed the absorbance of 1.7 and 1.9,
respectively. They were slightly increased survival under OGDLE
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Fig. 1. Screening of genes for cell survival under ischemia. (A) Cells were treated with the
and ischemic (white bars) conditions was measured by the absorbance of formazan prod
and screening condition. (C) Ischemic cell survival in the knockdown of 2-OG-Fe(II) dioxy
by dotted line. Results represent mean ± S.D. (n = 3).conditions, but knockdown of EGLN1 and EGLN3 (also known as
PHD2 and PHD3) induced cell death (Fig. 1C). Among these genes,
function of OGFOD1 (FLJ10826) is unclear and it was selected as
the most viable for further validation and characterization. Cells
with a silenced OGFOD1 gene survived under both normoxic and
OGD conditions (Fig. 2A and B). We also conﬁrmed that OGFOD1
protein levels were decreased by siRNA under our experimental
conditions (Fig. 2C).
3.2. Cellular localization of OGFOD1
OGFOD1 has >80% identity between human (542 amino acids)
and mouse (545 amino acids). From the NCBI database, the N-ter-
minal region in OGFOD1 was predicted to contain the prolyl 4-
hydoxylase (P4H) domain (Fig. 3A). A BLAST search and alignment
analysis indicated that the P4H domain of OGFOD1 shares 35–40%
identity with theSchizosaccharomyces pombeOfd1 orSaccharomycessiRNA 
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Fig. 2. Cell viability with OGFOD1 knockdown. (A) OGFOD1 knockdown cells were exposed to ischemia for four days. Cell viability under normoxia (black bars) and ischemia
(white bars) was measured by the absorbance of formazan products. Results are represented as means ± S.D. (n = 6, *P < 0.01). (B) Cell death under ischemia was indicated by
morphology of cells and PI staining. Scale bar = 50 lm. (C) OGFOD1 knockdown was detected by western blotting.
3342 K. Saito et al. / FEBS Letters 584 (2010) 3340–3347cerevisiae TPA1 genes (Fig. 3B); regions other than the P4H domain
have little homology (<20% identity). The N-terminal region of OG-
FOD1 also contains a positively charged amino acid sequence
(Fig. 3A, underlined), most likely correlating to a nuclear localiza-
tion signal. To determine the cellular localization of OGFOD1,
EGFP-OGFOD1 (wild-type) and nuclear localization signal-deleted
EGFP-OGFOD1 (DNLS) expression plasmids were transfected into
HeLa cells.Wild-type expressionwas localized to the nucleus, while
the mutant OGFOD1 (DNLS) expression was not (Fig. 3C). OGFOD1
translocation in response to changes in oxygen concentration re-
sulted in similar nuclear localization of endogenous OGFOD1 under
both normoxic and ischemic conditions, indicating that OGFOD1
functions in the nucleus (Fig. 3D).
3.3. Downregulated genes in OGFOD1 KO cells
To investigate OGFOD1 function, we generated an OGFOD1
knockout cell line using human Nalm6 cells. The Nalm6 cell line
provides convenient and high-efﬁciency gene targeting [14]. We
disrupted exons 5–8 of the P4H domain (Fig. 4A) by substitution
with both hygromycin and puromycin resistance genes. In South-
ern blot analysis, OGFOD1hyg/+ and OGFOD1hyg/puro cells revealed
bands of 7.0 kb and 8.6 kb, respectively (Fig. 4B, left). Wild-type
cells, but not OGFOD1 KO (OGFOD1hyg/puro) cells expressed OG-
FOD1 (Fig 4B, right). This OGFOD1 KO cells had more viability than
wild-type cells under ischemia (Fig. 4C).
Next, to understand how OGFOD1 KO results in ischemic cell
survival, we analyzed gene expression by cDNA microarray and
qRT-PCR. Our cDNA microarray analysis showed genes that were
up- and downregulated by at least threefold in OGFOD1 KO cells(OGFOD1hyg/puro) compared to wild-type cells (Table S2, GEO acces-
sion number: GSE21557). Quantiﬁcation of mRNA levels using
qRT-PCR showed a 1.5-fold change that corresponded to the micro-
array data, except for the NAALADL2 and COX1 genes (Table S3).
Taken together, the expression levels of many genes were down-
regulated in OGFOD1 KO cells.
3.4. Regulation of ATPAF1 expression by OGFOD1
To conﬁrm whether OGFOD1 modulates the downregulation of
genes, we reintroduced a OGFOD1 wild-type gene into the OGFOD1
KO cells (revWT) and found that revWT expression recovered only
ATPAF1 mRNA levels among the downregulated genes (Table S4).
This result indicates that the intact OGFOD1 appears to dominantly
regulate ATPAF1 mRNA levels over the other downregulated genes.
Therefore, we focused on the ATPAF1 gene for further studies of
OGFOD1 function and examined whether the structure and regula-
tion of OGFOD1 are important for expression of the ATPAF1 gene.
We generated an OGFOD1 H155A mutant that substitutes the
conserved His with Ala, a residue that along with Asp is located
within the P4H domain and is important for iron coordination in
the active site (Fig. 5A) [15,16]. We also generated an OGFOD1 C
and OGFOD1 N mutants (Fig. 5A). Although these mutants were
stably introduced into OGFOD1 KO cells, re-expression of ATPAF1
was not restored by revH155A, revN, or revC (Fig. 5B); the N-termi-
nal domain of OGFOD1 (revN) is an unstable protein fragment
(Fig. 5C). Furthermore, we examined the cell survival of revartant
cell lines under OGD conditions. The cells of revC or revH155A sig-
niﬁcantly reduced the cell death under OGD compared with wild-
type cells (Fig. 5D). The cell survival of revC was the same as that of
Fig. 3. Localization of OGFOD1 in the nucleus. (A) Domain structure of OGFOD1 was shown. (B) Sequence alignment of the P4H domain of TPA1, Ofd1, and OGFOD1. Residues
predicted to be required for iron coordination are indicated by an asterisk. Conserved residues are shown in the gray box. (C) The localization of OGFOD1 (wild-type) and
OGFOD1 (DNLS) was shown. Nuclei were stained with DAPI. Scale bar = 10 lm. (D) Endogenous OGFOD1 under normoxia and ischemia was shown. Scale bar = 10 lm.
K. Saito et al. / FEBS Letters 584 (2010) 3340–3347 3343OGFOD1 KO cells. These results conﬁrm that the iron-coordinating
residue is required for ATPAF1 expression and cell death under
OGD conditions.
Under OGD conditions, endogenous ATPAF1 and OGFOD1
mRNA levels decreased in wild-type cells (Fig. S1A). To examine
whether decreased ATPAF1 mRNA levels under OGD conditions
correlate with OGFOD1 protein expression levels, FLAG-OGFOD1
was overexpressed in HeLa cells (Fig. S1B). We found that the
expression levels of FLAG-OGFOD1 did not increase ATPAF1
mRNA levels in normal and OGD condition (Fig. S1C). In the cell
survival assay under OGD, increased expression of FLAG-OG-
FOD1 had no effect on cell survival (Fig. S1D). Thus, we con-
cluded that ATPAF1 mRNA expression required the activity of
OGFOD1 P4H domain rather than OGFOD1 protein expression
levels.
The yeast homolog of ATPAF1, ATP11p, has been reported to be
a mitochondrial F1-ATPase assembly factor [17,18]. We conﬁrmed
that ATPAF1 was co-localized with the mitochondrial maker,
DsRed-Mito, in HeLa cells (Fig. 6A, left). Moreover, introduction
of the ATPAF1 gene into OGFOD1 KO cells (Fig. 6A, right) signiﬁ-
cantly increased cell death under OGD compared with OGFOD1
KO cells (Fig. 6B).4. Discussion
We identiﬁed the OGFOD1 gene, a member of the 2-OG-Fe(II)
dioxygenase family, that plays an important role in ischemic sur-
vival. It is well known that loss of PHDs and FIH (EGLN1, 2, 3 and
HIF1AN) stabilize the HIF for hypoxic adaptation. However, knock-
down of EGLN1, 2, 3 and HIF1AN genes in our siRNA library screen-
ing had no signiﬁcant effect on ischemic survival compared to
knockdown of Ogfod1 gene (Fig. 1). We found that HIF-1a expres-
sion in OGFOD1 KO cells was slightly lower compared to wild-type
cells and PHDs expression were not difference between OGFOD1
wild-type and KO cells (Fig. S2A), suggesting that PHDs, FIH, and
OGFOD1 might recognize different substrates and play different
roles in cell survival.
The S. pombe ortholog of OGFOD1, Ofd1 degrades the Sre1 ma-
ture form (Sre1N) and an Ofd1-deﬁcient strain accumulates Sre1N
[19], which is an ortholog of the human sterol regulatory element
binding protein (SREBP). Ofd1 has a molecular mechanism where-
by the C-terminal region has catalytic activity under normoxia and
the activity was suppressed by the binding of Nro1 protein under
hypoxia [20]. In our study, OGFOD1 KO cells had little inﬂuence
on the accumulation of SREBP (Fig. S2B) and loss of OGFOD1
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3344 K. Saito et al. / FEBS Letters 584 (2010) 3340–3347decreased the ATPAF1 expression as well as the revH155A and revC
cell lines (Fig. 5). Thus, we found that the iron-coordinating residue
is required for ATPAF1 gene expression. If OGFOD1 has the same
intramolecular or intermolecular mechanism with Ofd1, it is
thought that OGFOD1 accumulate a negative regulator of ATPAF1
expression under ischemia. Further investigation is needed to
determine the molecular mechanism underlying the decrease in
ATPAF1 in OGFOD1 KO cells.
Although the substrate of OGFOD1 is currently unclear, several
reports provide speculative evidence that OGFOD1 functions innucleus (Fig. 3).Many2-OG-Fe(II) dioxygenases in the nucleus func-
tion as demethylases for the methylated DNA, RNA and histones
[21]. Studies of TPA1, an OGFOD1 ortholog in S. cerevisiae, have sug-
gested control of translation termination, mRNA poly(A) tail length,
and mRNA stability [22]. TPA1 has also been co-puriﬁed with the
NuA3 histone H3 HAT complex [23]. Thus, OGFOD1may cooperates
with the translation termination or histone modiﬁcation complex.
As shown in Fig. S2C, we found that Lys 9 methylation on histone
H3 levels in OGFOD1 KO cells was lower compared to wild-type
cells. Therefore, OGFOD1 may regulates transcription through the
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K. Saito et al. / FEBS Letters 584 (2010) 3340–3347 3345chromatin structure. It will be interesting to investigate whether
histone H3 modiﬁcations can regulate ATPAF1 transcription, and
whethermitochondrial ATPAF1expressioncontributes to the reduc-
tion of ADP/ATP ratio (Fig. S3) and cell death (Fig. 6). We also could
not rule out the possibility that loss of OGFOD1 reduces cell death by
mechanismother than controllingATPAF1expression, sinceATPAF1
levels in revN cell lines were not coincident with cell death (Fig. 5).Finally, we propose that intact OGFOD1 iron binding residues
are required for ATPAF1 gene expression and that changes in the
activity/structure of OGFOD1 induce cell survival under ischemic
conditions. These results and further studies of OGFOD1 will im-
prove the understanding of cell survival under ischemic conditions
including brain stroke, as OGFOD1 was found to be more abundant
in the brain (Fig. S4).
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